MovDisordV3, PascalFrancis, Corpus, bibRecord, 000095

Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study

Identifieur interne : 000095 ( PascalFrancis/Corpus ); précédent : 000094; suivant : 000096

Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study

Auteurs : Bruno Dubois ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Gunther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. Moline

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0369631

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Démence, Pathologie du système nerveux, Donépézil, Etude double insu, Sécurité, Cognition, Fonction exécutive, Cholinesterase.

English descriptors

KwdEn :
- Cholinesterase, Cognition, Dementia, Donepezil, Double blind study, Executive function, Nervous system diseases, Parkinson disease, Safety.

Abstract

Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study`
A11	`01`	`1`		`@1 DUBOIS (Bruno)`
A11	`02`	`1`		`@1 TOLOSA (Eduardo)`
A11	`03`	`1`		`@1 KATZENSCHLAGER (Regina)`
A11	`04`	`1`		`@1 EMRE (Murat)`
A11	`05`	`1`		`@1 LEES (Andrew J.)`
A11	`06`	`1`		`@1 SCHUMANN (Gunther)`
A11	`07`	`1`		`@1 POURCHER (Emmanuelle)`
A11	`08`	`1`		`@1 GRAY (Julian)`
A11	`09`	`1`		`@1 THOMAS (Gail)`
A11	`10`	`1`		`@1 SWARTZ (Jina)`
A11	`11`	`1`		`@1 HSU (Timothy)`
A11	`12`	`1`		`@1 MOLINE (Margaret L.)`
A14	`01`			`@1 Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975 @2 Paris @3 FRA @Z 1 aut.`
A14	`02`			`@1 Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona @2 Barcelona @3 ESP @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Donauspital/SMZ-Ost @2 Vienna @3 AUT @Z 3 aut.`
A14	`04`			`@1 Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit @2 Istanbul @3 TUR @Z 4 aut.`
A14	`05`			`@1 Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square @2 London @3 GBR @Z 5 aut.`
A14	`06`			`@1 Castroper Hellweg 422 44805 @2 Bochum @3 DEU @Z 6 aut.`
A14	`07`			`@1 Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne @2 Quebec @3 CAN @Z 7 aut.`
A14	`08`			`@1 McArthur and Associates GmbH @2 Basel @3 CHE @Z 8 aut.`
A14	`09`			`@1 Eisai Limited @2 Hatfield @3 GBR @Z 9 aut. @Z 10 aut.`
A14	`10`			`@1 Eisai Inc., Woodcliff Lake @2 New Jersey @3 USA @Z 11 aut. @Z 12 aut.`
A20				`@1 1230-1238`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000502011860090`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 12-0369631`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Démence @5 02`
C03	`02`	`X`	`ENG`	`@0 Dementia @5 02`
C03	`02`	`X`	`SPA`	`@0 Demencia @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Donépézil @2 NK @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Donepezil @2 NK @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Donepezilo @2 NK @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Etude double insu @5 10`
C03	`05`	`X`	`ENG`	`@0 Double blind study @5 10`
C03	`05`	`X`	`SPA`	`@0 Estudio doble ciego @5 10`
C03	`06`	`X`	`FRE`	`@0 Sécurité @5 11`
C03	`06`	`X`	`ENG`	`@0 Safety @5 11`
C03	`06`	`X`	`SPA`	`@0 Seguridad @5 11`
C03	`07`	`X`	`FRE`	`@0 Cognition @5 12`
C03	`07`	`X`	`ENG`	`@0 Cognition @5 12`
C03	`07`	`X`	`SPA`	`@0 Cognición @5 12`
C03	`08`	`X`	`FRE`	`@0 Fonction exécutive @5 13`
C03	`08`	`X`	`ENG`	`@0 Executive function @5 13`
C03	`08`	`X`	`SPA`	`@0 Función ejecutiva @5 13`
C03	`09`	`X`	`FRE`	`@0 Cholinesterase @2 FE @5 14`
C03	`09`	`X`	`ENG`	`@0 Cholinesterase @2 FE @5 14`
C03	`09`	`X`	`SPA`	`@0 Cholinesterase @2 FE @5 14`
C07	`01`	`X`	`FRE`	`@0 Carboxylic ester hydrolases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Carboxylic ester hydrolases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Carboxylic ester hydrolases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Esterases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Esterases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Esterases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`04`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`05`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`05`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`06`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`06`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`07`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`07`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`07`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 289`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0369631 INIST
ET :	Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study
AU :	DUBOIS (Bruno); TOLOSA (Eduardo); KATZENSCHLAGER (Regina); EMRE (Murat); LEES (Andrew J.); SCHUMANN (Gunther); POURCHER (Emmanuelle); GRAY (Julian); THOMAS (Gail); SWARTZ (Jina); HSU (Timothy); MOLINE (Margaret L.)
AF :	Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975/Paris/France (1 aut.); Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona/Barcelona/Espagne (2 aut.); Department of Neurology, Donauspital/SMZ-Ost/Vienna/Autriche (3 aut.); Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit/Istanbul/Turquie (4 aut.); Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (5 aut.); Castroper Hellweg 422 44805/Bochum/Allemagne (6 aut.); Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne/Quebec/Canada (7 aut.); McArthur and Associates GmbH/Basel/Suisse (8 aut.); Eisai Limited/Hatfield/Royaume-Uni (9 aut., 10 aut.); Eisai Inc., Woodcliff Lake/New Jersey/Etats-Unis (11 aut., 12 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 10; Pp. 1230-1238; Bibl. 31 ref.
LA :	Anglais
EA :	Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Démence; Pathologie du système nerveux; Donépézil; Etude double insu; Sécurité; Cognition; Fonction exécutive; Cholinesterase
FG :	Carboxylic ester hydrolases; Esterases; Hydrolases; Enzyme; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Dementia; Nervous system diseases; Donepezil; Double blind study; Safety; Cognition; Executive function; Cholinesterase
EG :	Carboxylic ester hydrolases; Esterases; Hydrolases; Enzyme; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Demencia; Sistema nervioso patología; Donepezilo; Estudio doble ciego; Seguridad; Cognición; Función ejecutiva; Cholinesterase
LO :	INIST-20953.354000502011860090
ID :	12-0369631

Links to Exploration step

Pascal:12-0369631

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study</title>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
<affiliation><inist:fA14 i1="04"><s1>Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="05"><s1>Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schumann, Gunther" sort="Schumann, Gunther" uniqKey="Schumann G" first="Gunther" last="Schumann">Gunther Schumann</name>
<affiliation><inist:fA14 i1="06"><s1>Castroper Hellweg 422 44805</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation><inist:fA14 i1="07"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gray, Julian" sort="Gray, Julian" uniqKey="Gray J" first="Julian" last="Gray">Julian Gray</name>
<affiliation><inist:fA14 i1="08"><s1>McArthur and Associates GmbH</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thomas, Gail" sort="Thomas, Gail" uniqKey="Thomas G" first="Gail" last="Thomas">Gail Thomas</name>
<affiliation><inist:fA14 i1="09"><s1>Eisai Limited</s1>
<s2>Hatfield</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Swartz, Jina" sort="Swartz, Jina" uniqKey="Swartz J" first="Jina" last="Swartz">Jina Swartz</name>
<affiliation><inist:fA14 i1="09"><s1>Eisai Limited</s1>
<s2>Hatfield</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hsu, Timothy" sort="Hsu, Timothy" uniqKey="Hsu T" first="Timothy" last="Hsu">Timothy Hsu</name>
<affiliation><inist:fA14 i1="10"><s1>Eisai Inc., Woodcliff Lake</s1>
<s2>New Jersey</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moline, Margaret L" sort="Moline, Margaret L" uniqKey="Moline M" first="Margaret L." last="Moline">Margaret L. Moline</name>
<affiliation><inist:fA14 i1="10"><s1>Eisai Inc., Woodcliff Lake</s1>
<s2>New Jersey</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0369631</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0369631 INIST</idno>
<idno type="RBID">Pascal:12-0369631</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000095</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study</title>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
<affiliation><inist:fA14 i1="04"><s1>Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="05"><s1>Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schumann, Gunther" sort="Schumann, Gunther" uniqKey="Schumann G" first="Gunther" last="Schumann">Gunther Schumann</name>
<affiliation><inist:fA14 i1="06"><s1>Castroper Hellweg 422 44805</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
<affiliation><inist:fA14 i1="07"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gray, Julian" sort="Gray, Julian" uniqKey="Gray J" first="Julian" last="Gray">Julian Gray</name>
<affiliation><inist:fA14 i1="08"><s1>McArthur and Associates GmbH</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thomas, Gail" sort="Thomas, Gail" uniqKey="Thomas G" first="Gail" last="Thomas">Gail Thomas</name>
<affiliation><inist:fA14 i1="09"><s1>Eisai Limited</s1>
<s2>Hatfield</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Swartz, Jina" sort="Swartz, Jina" uniqKey="Swartz J" first="Jina" last="Swartz">Jina Swartz</name>
<affiliation><inist:fA14 i1="09"><s1>Eisai Limited</s1>
<s2>Hatfield</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hsu, Timothy" sort="Hsu, Timothy" uniqKey="Hsu T" first="Timothy" last="Hsu">Timothy Hsu</name>
<affiliation><inist:fA14 i1="10"><s1>Eisai Inc., Woodcliff Lake</s1>
<s2>New Jersey</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moline, Margaret L" sort="Moline, Margaret L" uniqKey="Moline M" first="Margaret L." last="Moline">Margaret L. Moline</name>
<affiliation><inist:fA14 i1="10"><s1>Eisai Inc., Woodcliff Lake</s1>
<s2>New Jersey</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cholinesterase</term>
<term>Cognition</term>
<term>Dementia</term>
<term>Donepezil</term>
<term>Double blind study</term>
<term>Executive function</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Safety</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Démence</term>
<term>Pathologie du   système nerveux</term>
<term>Donépézil</term>
<term>Etude double insu</term>
<term>Sécurité</term>
<term>Cognition</term>
<term>Fonction exécutive</term>
<term>Cholinesterase</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DUBOIS (Bruno)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TOLOSA (Eduardo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KATZENSCHLAGER (Regina)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>EMRE (Murat)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEES (Andrew J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SCHUMANN (Gunther)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>POURCHER (Emmanuelle)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GRAY (Julian)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>THOMAS (Gail)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>SWARTZ (Jina)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>HSU (Timothy)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MOLINE (Margaret L.)</s1>
</fA11>
<fA14 i1="01"><s1>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Donauspital/SMZ-Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Castroper Hellweg 422 44805</s1>
<s2>Bochum</s2>
<s3>DEU</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>McArthur and Associates GmbH</s1>
<s2>Basel</s2>
<s3>CHE</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Eisai Limited</s1>
<s2>Hatfield</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Eisai Inc., Woodcliff Lake</s1>
<s2>New Jersey</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>1230-1238</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000502011860090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0369631</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Démence</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dementia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Demencia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Donépézil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Donepezil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Donepezilo</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Sécurité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Safety</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Seguridad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cognition</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cognition</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cognición</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Fonction exécutive</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Executive function</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Función ejecutiva</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cholinesterase</s0>
<s2>FE</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>289</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0369631 INIST</NO>
<ET>Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study</ET>
<AU>DUBOIS (Bruno); TOLOSA (Eduardo); KATZENSCHLAGER (Regina); EMRE (Murat); LEES (Andrew J.); SCHUMANN (Gunther); POURCHER (Emmanuelle); GRAY (Julian); THOMAS (Gail); SWARTZ (Jina); HSU (Timothy); MOLINE (Margaret L.)</AU>
<AF>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d'Alzheimer (IMMA); Inserm U 975/Paris/France (1 aut.); Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona/Barcelona/Espagne (2 aut.); Department of Neurology, Donauspital/SMZ-Ost/Vienna/Autriche (3 aut.); Istanbul University, Department of Neurology, Behavioral Neurology and Movement Disorders Unit/Istanbul/Turquie (4 aut.); Reta Lila Weston Institute of Neurological Studies and the National Hospital for Neurology and Neurosurgery, Queen Square/London/Royaume-Uni (5 aut.); Castroper Hellweg 422 44805/Bochum/Allemagne (6 aut.); Quebec Memory and Motor Skills Disorders Research Center, Clinique Sainte Anne/Quebec/Canada (7 aut.); McArthur and Associates GmbH/Basel/Suisse (8 aut.); Eisai Limited/Hatfield/Royaume-Uni (9 aut., 10 aut.); Eisai Inc., Woodcliff Lake/New Jersey/Etats-Unis (11 aut., 12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 10; Pp. 1230-1238; Bibl. 31 ref.</SO>
<LA>Anglais</LA>
<EA>Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P <.001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Démence; Pathologie du   système nerveux; Donépézil; Etude double insu; Sécurité; Cognition; Fonction exécutive; Cholinesterase</FD>
<FG>Carboxylic ester hydrolases; Esterases; Hydrolases; Enzyme; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Dementia; Nervous system diseases; Donepezil; Double blind study; Safety; Cognition; Executive function; Cholinesterase</ED>
<EG>Carboxylic ester hydrolases; Esterases; Hydrolases; Enzyme; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Demencia; Sistema nervioso patología; Donepezilo; Estudio doble ciego; Seguridad; Cognición; Función ejecutiva; Cholinesterase</SD>
<LO>INIST-20953.354000502011860090</LO>
<ID>12-0369631</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000095 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000095 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0369631
   |texte=   Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study

Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri